Biotech companies directory 2026

    Biotech Companies in the UAE

    Biotechnology in the United Arab Emirates is a hub, capital and regulation play: sovereign platforms buy genomics, parks and fill-finish, while discovery chemistry still arrives from Boston, Basel, Shanghai or London rather than from a dense local start-up cluster.

    M42, formed when G42 Healthcare merged with Mubadala Health, now holds the Emirati Genome Programme, the Omics Center of Excellence and the Abu Dhabi Biobank, and it signs the gene-editing and longevity partnerships that give the country a visible life-science story. PureHealth folds SEHA hospitals, Daman and the Abu Dhabi Stem Cells Center into one listed group. Hayat Biotech, the G42–Sinopharm CNBG joint venture, runs a vial plant in KEZAD. Julphar in Ras Al Khaimah remains the only Gulf manufacturer with dedicated insulin and erythropoietin drug-substance suites. Around them sit university laboratories at New York University Abu Dhabi, Khalifa University, UAE University and the University of Sharjah, plus tenants of Dubai Science Park that sell reagents and instruments rather than molecules. MOHAP, DoH Abu Dhabi and DHA split the licence, so a partnering team has to know which emirate owns the file before it asks who will manufacture. BioNixus sets the names out by function — sovereign platform, biologics plant, academic engine, park tenant, regulator — so a licensing or market-access conversation starts with the right door.

    Updated September 2026 · Ministry of Health and Prevention (MOHAP) — registered biological products and licensed establishments as of September 2026 · 17 named accounts

    Request a proposal for the UAEBrowse the 17 companies

    3

    Health regulators that licence biologics and research (MOHAP, DoH Abu Dhabi, DHA)

    ~800k

    Whole genomes M42 reports as sequenced under the Emirati Genome Programme

    200m

    Vials a year of stated filling capacity at Hayat Biotech’s KEZAD plant

    40m

    Insulin vials a year of published capacity at Julphar’s Ras Al Khaimah biologics campus

    Named accounts

    Top biotechnology companies in the UAE

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Ministry of Health and Prevention (MOHAP) — registered biological products and licensed establishments (as of 2026-09-04).
    #CompanyHQ
    01M42 (including former G42 Healthcare)Abu Dhabi
    02PureHealthAbu Dhabi
    03Hayat BiotechAbu Dhabi
    04Julphar (Gulf Pharmaceutical Industries)Ras Al Khaimah
    05Abu Dhabi Stem Cells Center (ADSCC)Abu Dhabi
    06New York University Abu Dhabi — biology and bioengineering researchAbu Dhabi
    07Khalifa University — Center for BiotechnologyAbu Dhabi
    08United Arab Emirates University — College of Medicine and Health SciencesAl Ain
    09Mohammed Bin Rashid University of Medicine and Health Sciences (Dubai Health)Dubai
    10University of Sharjah — Research Institute of Medical and Health SciencesSharjah
    11NeopharmaAbu Dhabi
    12Dubai Science ParkDubai
    13Thermo Fisher Scientific — Dubai Science ParkDubai
    14Merck Life Science — regional hubDubai
    15Department of Health – Abu DhabiAbu Dhabi
    16Ministry of Health and Prevention (MOHAP)Dubai
    17Dubai Health Authority — research and innovationDubai

    Primary research

    These are the biotech and innovation accounts we track in the UAE

    Partnering, licensing or launching a biologic in the UAE? BioNixus runs KOL, payer and regulator interviews plus hospital-level demand sizing. Proposal within 48 hours.

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in the UAE (2026)

    How the market is structured

    How capital, parks and regulators shape biotechnology in the UAE

    Money and licences travel faster than discovery here. Abu Dhabi sovereign capital funds M42 and PureHealth, which then buy platforms, sequence citizens, bank samples and invite foreign developers to run studies or transfer filling. Dubai Science Park, which absorbed the older DuBiotech free zone, leases wet-lab and distribution space to instrument and reagent houses; it is a logistics and commercial address, not a Genentech campus. Ras Al Khaimah hosts Julphar’s insulin crystal and cartridge lines, the one piece of upstream biologics manufacturing that predates the pandemic wave of announcements. Hayat Biotech’s KEZAD factory was built for Sinopharm antigens and is now offered as regional contract filling. Registration of a biologic still needs a UAE marketing authorisation holder and inspection by the emirate that owns the plant or the importer: MOHAP for federal files and the northern emirates, DoH for Abu Dhabi manufacturing and research, DHA for Dubai Healthcare City and Dubai hospital use. Pricing follows the Ministry’s unified list, while Abu Dhabi’s Jawda and DoH innovation pathways can speed first use of a cell or gene therapy inside SEHA and Cleveland Clinic Abu Dhabi. Demand is insurance-funded in Dubai and Abu Dhabi, so a locally filled insulin or biosimilar still has to win Daman, Sukoon and GIG formularies after it clears the regulator. Partnering therefore runs through four rooms — M42 or PureHealth for data and sites, Julphar or Hayat for steel, a university for investigators, and the emirate regulator for the licence — and a team that treats the UAE as a deep discovery cluster will waste a year talking to the wrong counterpart.

    Local

    Sovereign-backed platforms and the two plants that actually make or fill biologics — M42, Hayat Biotech, Julphar and Neopharma — plus the listed PureHealth system that owns beds and an insurer.

    • M42 (including former G42 Healthcare)
    • Hayat Biotech
    • Julphar (Gulf Pharmaceutical Industries)
    • Neopharma

    Multinational

    NYU’s Saadiyat campus and the Science Park instrument houses that bring foreign kits, freezers and teaching labs rather than a UAE-invented molecule.

    • New York University Abu Dhabi — biology and bioengineering research
    • Thermo Fisher Scientific — Dubai Science Park
    • Merck Life Science — regional hub

    Regional

    Gulf manufacturers with UAE plants or offices appear in this market mainly as Julphar itself; most other regional houses still treat the Emirates as a commercial hub, not a drug-substance site.

    Incubators, CDMOs & partners

    Federal and emirate regulators, Dubai Science Park as landlord, and the university institutes that supply investigators and ethics committees.

    • PureHealth
    • Abu Dhabi Stem Cells Center (ADSCC)
    • Khalifa University — Center for Biotechnology
    • United Arab Emirates University — College of Medicine and Health Sciences
    • Mohammed Bin Rashid University of Medicine and Health Sciences (Dubai Health)
    • University of Sharjah — Research Institute of Medical and Health Sciences
    • Dubai Science Park
    • Department of Health – Abu Dhabi
    • Ministry of Health and Prevention (MOHAP)
    • Dubai Health Authority — research and innovation

    What is moving

    What is moving biotechnology in the UAE

    Sovereign genomics and biobank scale

    M42’s sequenced Emirati cohort and Abu Dhabi Biobank give foreign developers a reason to place observational and precision-medicine work in Abu Dhabi even when the molecule was discovered elsewhere.

    Fill-finish and insulin steel already standing

    Hayat’s KEZAD vials and Julphar’s Ras Al Khaimah crystals are usable assets today; localisation talks start from those suites instead of from a greenfield promise.

    Split but digital regulation

    DoH, DHA and MOHAP still split the map, yet Malaffi, NABIDH and Jawda let a first-use advanced therapy be watched in real time once an emirate licence is in hand.

    Insurance-funded tertiary hospitals

    Mandatory cover in Dubai and Abu Dhabi plus Cleveland Clinic Abu Dhabi and SEHA tertiary sites create a paying launch pad for cell therapy and high-cost biologics that thinner Gulf markets cannot match.

    BioNixus fieldwork

    How BioNixus studies biotechnology companies in the UAE

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in the UAE:
    • Pharmacist and formulary interviews at SEHA, Cleveland Clinic Abu Dhabi and Dubai Health hospitals on originator-versus-locally-filled insulin and erythropoietin.
    • Licence-pathway mapping with DoH Abu Dhabi, DHA and MOHAP officers that separates federal product files from emirate research permits.
    • Plant-visit and capacity discussions in Ras Al Khaimah (Julphar) and KEZAD (Hayat) focused on what is commissioned versus announced.
    • Investigator interviews at NYU Abu Dhabi, Khalifa University and MBRU on what industry protocols they can actually host.

    Biotech market research in the UAE

    Questions

    Frequently Asked Questions

    Is the UAE a discovery biotechnology cluster?

    Not in the Boston or Cambridge sense. The country buys platforms, sequences a national cohort, fills vials and licences foreign molecules. Julphar’s insulin suites are the main exception on drug substance. Treat the market as capital, regulation and late-stage infrastructure.

    Who should a foreign developer call first in Abu Dhabi?

    M42 if the need is genomics, biobank access or a health-system research partnership; DoH if the need is an ATMP or research licence; Hayat or Julphar if the need is filling or insulin-related manufacturing; PureHealth or ADSCC if the need is hospital-based cell therapy.

    Which authority registers a biologic for national sale?

    MOHAP issues the federal marketing authorisation and price. DoH and DHA still govern research, facility licences and first use inside their emirates, so a file often has a federal product number and an emirate research number.

    What does Dubai Science Park actually host?

    Regional headquarters, distribution warehouses and application laboratories for instrument and reagent companies, plus a smaller set of manufacturing and compounding tenants. It is not a pipeline of UAE-origin monoclonal antibodies.

    What fieldwork does BioNixus run on UAE biotechnology organisations?

    Stakeholder interviews in Abu Dhabi, Dubai and Ras Al Khaimah with hospital pharmacists, DoH and DHA research officers, and plant managers; mapping of which emirate owns a given licence; and account studies on how Daman and SEHA treat locally filled insulin versus imported originator packs.

    Should readers treat this list as a league table of UAE biotech firms?

    Treat it as a role map. Names are here because they keep appearing in BioNixus UAE interviews and in MOHAP, DoH and ADX disclosures. Sequence follows function — platform, plant, campus, park, regulator — not valuation or headcount.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in the UAE. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Ministry of Health and Prevention (MOHAP) — registered biological products and licensed establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / incubators, cdmos & partners) reflects ownership and role in the UAE, not size.

    • M42 public announcements on the Emirati Genome Programme, Abu Dhabi Biobank and life-science partnerships, 2024–2026
    • Hayat Biotech and Department of Health – Abu Dhabi statements on the KEZAD filling plant
    • Julphar (Gulf Pharmaceutical Industries) disclosures on insulin and erythropoietin facilities and the Sunshine Lake analogue licence
    • BioNixus UAE biotechnology and hospital-pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need biotech and biologics market data in the UAE?

    Payer appetite, biosimilar uptake, KOL sentiment and tender exposure — primary research, not desk estimates.

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. Proposals within 48 hours.